Stock Titan Trading tools for traders and investors.

-

05:29:12 PM

Last BCLI Stock Market News

BCLI - Brainstorm Cell Therapeutics, Inc.

02/26/21 11:00 AM

Nasdaq : BCLI

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI). Investors who purchased Brainstorm securities are encouraged to obtain additional information and assist the

RHEA-AI

negative

02/24/21 2:50 PM

Nasdaq : BCLI

Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Brainstorm Cell Therapeutics Inc. ("Brainstorm" or "the Company") (NASDAQ: BCLI). Investors who purchased Brainstorm securities are encouraged to obtain additional information and

RHEA-AI

negative

02/23/21 8:00 AM

Nasdaq : BCLI

BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will participate in the 10 th Annual SVB Leerink Global Healthcare

RHEA-AI

neutral

02/22/21 8:05 AM

Nasdaq : BCLI

BrainStorm Announces High-Level FDA Feedback on NurOwn(R) ALS Clinical Development Program

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently met with senior leadership from the U.S. Food and Drug Administration (FDA) and received FDA

RHEA-AI

neutral

02/09/21 9:00 AM

Nasdaq : BCLI

BrainStorm Announces Feedback from FDA Type-C Meeting on Future NurOwn(R) Manufacturing Plan

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that it recently concluded a Type C meeting with the U.S. Food and Drug Administration (FDA) to review specific

RHEA-AI

neutral

02/04/21 7:00 AM

Nasdaq : BCLI

BrainStorm Announces Full Year 2020 Financial Results and Provides a Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the fiscal year ended December 31, 2020, and provided a corporate update."In 2020 we achieved

RHEA-AI

neutral

01/28/21 8:30 AM

Nasdaq : BCLI, BLCI

BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update

BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on

RHEA-AI

neutral

01/20/21 9:08 AM

Nasdaq : BCLI

BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn(R) Derived Exosome-Based Treatment for COVID-19 ARDS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy. The study,

RHEA-AI

positive

12/28/20 7:00 AM

Nasdaq : BCLI

BrainStorm Issues 2020 Letter to Shareholders

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the following letter from its Chief Executive Officer, Chaim Lebovits, to its shareholders and the investment

RHEA-AI

positive

12/18/20 7:00 AM

Nasdaq : BCLI

BrainStorm Announces Completion of All Dosing in NurOwn(R) Phase 2 MS Study

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that all dosing has been completed in the ongoing Phase 2 trial evaluating NurOwn(R) (MSC-NTF cells) as a

RHEA-AI

neutral